Interpath Global is expanding its investment in veterinary education and industry engagement following the successful launch and continued growth of 4CYTE™ Epiitalis® Forte Dog.
Originally developed to support joint health through Interpath’s patented plant seed oil Epiitalis®, the 4CYTE™ range has become one of Canada’s most recognised joint health brands, trusted by veterinarians, clinics, and pet owners alike.
While the brand has experienced strong organic growth over the past decade, Interpath is now increasing its focus on veterinary partnerships, education, and awareness initiatives across Canada.
“We’ve spent many years focused on research, product development, and delivering consistent outcomes in market,” said Rebecca Britton, CEO of Interpath Global.
“With the continued growth of 4CYTE™ and increasing awareness around proactive joint health management, now is the right time for us to invest more heavily in supporting the veterinary profession through education, collaboration, and broader industry engagement.”
The expansion comes as demand for joint health support continues to rise, particularly as pets live longer and owners seek proactive approaches to mobility and quality of life.
Unlike many traditional joint supplements, 4CYTE™ contains Epiitalis®, a patented plant seed oil ingredient developed through Interpath’s long-term research program. The company says its focus remains on delivering evidence-backed products that support both veterinary recommendation and owner compliance.
The launch of 4CYTE™ Epiitalis® Forte Dog last year has further strengthened the brand’s position within the companion animal market, providing veterinarians and pet owners with an easy-to-administer daily gel format designed to support long-term use.
As part of its expanded veterinary strategy, Interpath will increase:
- Veterinary education initiatives
- Conference and industry event participation
- Clinic partnership programs
- Support for veterinary teams and customers
Founded in Ballarat, Australia, Interpath has grown from a family-led innovation business into a global joint health company supplying products across companion animal, equine, and human health categories.
“Our mission has always been to improve quality of life through better joint health,” said Britton. “We’re excited about the next phase of growth and working even more closely with the veterinary industry moving forward.”
Hillar Sorra is the Canadian Country Manager who was instrumental in introducing their flagship product, Sasha Blend, to Canada. Hillar is passionate about joint health and his desire to provide best in class product solutions is what motivates Hillar with the launch of our new generation 4CYTE™ products.
The product is available through veterinary distribution companies. Veterinary teams may reach out directly to Hillar to discuss 4CYTE™ and its incredible support offerings or set up an appointment to present to clinic staff – hillar.sorra@interpath.global.
Learn more about 4CYTE™ and the world-class research by visiting their website.
About Interpath Global:
Interpath Global is a family-owned company pioneering research and development in the fields of human and animal joint health. They are committed to pushing boundaries via ongoing scientific exploration, to create innovative and unique products that drive change in the industry, and offer natural, effective solutions to those living with joint health problems. Learn more at https://ca.4cyte.global/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260608966689/en/
Media gallery
